A5067619404- Testicular diseases and treatments
- Sexual Differentiation and Disorders
- Sarcoma Diagnosis and Treatment
- Urologic and reproductive health conditions
- Ovarian cancer diagnosis and treatment
- Neuroblastoma Research and Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Sperm and Testicular Function
- Cancer Treatment and Pharmacology
- Genital Health and Disease
- Radiopharmaceutical Chemistry and Applications
- Chemotherapy-related skin toxicity
- Venous Thromboembolism Diagnosis and Management
- Chemotherapy-induced organ toxicity mitigation
- Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Advanced Radiotherapy Techniques
- Cancer survivorship and care
- Multiple Myeloma Research and Treatments
- Multiple and Secondary Primary Cancers
- Cancer, Lipids, and Metabolism
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
St Olav's University Hospital
2016-2025
Norwegian University of Science and Technology
2003-2025
Université Paris-Sud
2017
Kantonsspital St. Gallen
2017
University of St. Gallen
2017
University of British Columbia
2014-2017
Cancer Clinic
2015
BC Cancer Agency
2014
Princess Margaret Cancer Centre
2014
Ålesund Hospital
2009-2011
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
To evaluate the performance of active surveillance as a management strategy in broad populations and to inform development schedules by individual patient data regarding timing type relapse.Retrospective study including from 2,483 clinical stage I (CSI) patients, 1,139 CSI nonseminoma 1,344 seminoma managed with surveillance, majority treated between 1998 2010. Clinical outcomes relapse death, time distribution, extent method detection observed on were recorded.Relapse occurred 221 (19%)...
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held 3-5 November 2016 in Paris, France. included a multidisciplinary panel of 36 leading experts the diagnosis and treatment (34 members attended conference; an additional two [CB K-PD] participated all preparatory work subsequent manuscript development). aim to develop detailed recommendations topics relating that are not covered detail current ESMO Clinical Practice Guidelines (CPGs) where...
The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in management metastatic germ cell tumors but relies on data patients treated between 1975 and 1990.Data 9,728 men with nonseminomatous cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected from 30 institutions or collaborative groups Europe, North America, Australia. Clinical trial registry included. Primary end points progression-free survival (PFS) overall (OS)....
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in management germ-cell tumors, but relies on data only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this database from large international consortium.Data 2,451 men metastatic cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected 30 institutions or collaborative groups Australia, Europe, North America. Clinical trial registry...
To offer minimized risk-adapted adjuvant treatment on a nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce the risk of relapse and thereby reducing need later salvage chemotherapy while maintaining high cure rate.From 1998 2005, 745 Norwegian Swedish were included into prospective, community-based multicenter Testicular Cancer Project (SWENOTECA) management program. Treatment strategy depended presence or...
Purpose A binational, population-based treatment protocol was established to prospectively treat and follow patients with seminomatous testicular cancer. The aim standardize care for all seminoma further improve the good results expected this disease. Patients Methods From 2000 2006, a total of 1,384 Norwegian Swedish were included in study. Treatment clinical stage 1 (CS1) surveillance, adjuvant radiotherapy, or carboplatin. In metastatic disease, recommended radiotherapy CS2A...
From 1995 to 2003, 603 adult patients from Sweden and Norway with metastatic testicular nonseminomatous germ cell tumor (NSGCT) were included prospectively in a population-based protocol strict guidelines for staging, treatment, follow-up. Patients extragonadal primary or previous treatment contralateral excluded. The basic strategy was individualize according initial marker response.Initial all two courses of standard bleomycin, etoposide, cisplatin (BEP), markers analyzed weekly. Good...
Long-term relative survival (RS) data for testicular germ cell tumor (TGCT) patients are scarce. We aimed to analyze long-term RS among TGCT diagnosed in Norway, between 1953 and 2012.Data sources were the Cancer Registry of Norway Norwegian Cause Death Registry. during 2012 classified by time diagnosis, histology, age, disease extent at diagnosis. Estimates obtained, a test comparing overall was performed. Corresponding obtained men with localized malignant melanoma before age 50.A total...
Using complete information on total treatment burden, this population‐based study aimed to investigate second cancer (SC) risk in testicular survivors (TCS) treated the cisplatin era. The Cancer Registry of Norway identified 5,625 1‐year TCS diagnosed 1980–2009. Standardized incidence ratios (SIRs) were calculated evaluate and site‐specific SC compared general population. Cox regression analyses evaluated effect SC. After a median observation time 16.6 years, 572 developed 651 nongerm cell...
Using complete information regarding testicular cancer (TC) treatment burden, this study aimed to investigate cause-specific non-TC mortality with impact on previous platinum-based chemotherapy (PBCT) or radiotherapy (RT).Overall, 5,707 men identified by the Cancer Registry of Norway diagnosed TC from 1980 2009 were included in population-based cohort study. By linking data Norwegian Cause Death Registry, standardized ratios (SMRs), absolute excess risks (AERs; [(observed number deaths -...
There is an unmet need to avoid long-term morbidity associated with standard cytotoxic treatment for low-volume metastatic seminoma. Our aim was assess the oncological efficacy and surgical safety of retroperitoneal lymph node dissection (RPLND) as in a population-based cohort seminoma patients limited lymphadenopathy.
Purpose Adjuvant carboplatin is one of three management strategies that may follow inguinal orchiectomy in clinical stage I seminoma. However, little known about the outcome patients who experience a relapse after such treatment. Patients and Methods Data from 185 relapsed adjuvant between January 1987 August 2013 at 31 centers/groups 20 countries were collected retrospectively analyzed. Primary outcomes disease-free survival overall survival. Secondary time to, at, treatment as well rate...
Open AccessJournal of UrologyOriginal Clinical Article25 Jul 2024miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR StudyThis article is commented on by the following:Editorial Comment Anna Thor, Mette Pernille Myklebust, Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, and Anders Kjellman...